文献速递肝病消化道肿瘤与早癌

新辅助与辅助纳武利尤单抗联合不可逆电穿孔治疗高危复发早期肝细胞癌

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).
PubMed 文献 · Hepatology · 2026-04-08

NIVOLEP 是一项多中心 2 期试验,评估纳武利尤单抗联合不可逆电穿孔(IRE)治疗 BCLC A 期肝细胞癌。43 例患者接受 2 次新辅助纳武利尤单抗、根治性 IRE 及 12 次每月辅助纳武利尤单抗。1 年局部无复发生存率为 70.6%(95% CI: 55.3-85.9),2 年总生存率为 74.2%。

要点

  • 新辅助纳武利尤单抗后影像学或病理学缓解率分别为 24.2% 和 26.3%。
  • 1 年局部无复发生存率为 70.6%(95% CI: 55.3-85.9)。
  • 2 年总生存率为 74.2%(意向性治疗分析)。

核心结论

  • 新辅助与辅助纳武利尤单抗在适合 IRE 的 BCLC A 期肝细胞癌患者中诱导与免疫激活相关的病理学缓解,并显示抗肿瘤效应。

研究设计与样本

  • NIVOLEP 为多中心 2 期试验,评估纳武利尤单抗联合 IRE 治疗 BCLC A 期肝细胞癌。
  • 共纳入 43 例患者(平均年龄 71 岁,88% 男性,81% 肝硬化)的 62 个 HCC 结节(平均大小 30.0 mm)。
  • 患者接受 2 次新辅助纳武利尤单抗输注、根治性 IRE 及 12 次每月辅助纳武利尤单抗输注。
  • 主要终点为 1 年局部无复发生存率(LRFS)。

主要发现

  • 所有患者接受新辅助纳武利尤单抗;35 例接受根治性 IRE,其余 8 例中 4 例 IRE 失败、3 例 HCC 进展、1 例死亡。
  • 新辅助纳武利尤单抗后,影像学缓解见于 24.2% 的结节,病理学缓解见于 26.3% 的结节。
  • 1 年 LRFS 为 70.6%(95% CI: 55.3-85.9),2 年总生存率为 74.2%(意向性治疗分析)。
  • 2 例患者发生与纳武利尤单抗相关的 3 或 4 级不良事件;1 例患者因纳武利尤单抗死亡。
  • 新辅助纳武利尤单抗后肿瘤 RNA 测序显示与病理学缓解相关的白细胞迁移、T 细胞活化及 CD8+ T 细胞和 B 细胞浸润通路富集。

临床怎么用

  • 对于适合 IRE 的 BCLC A 期肝细胞癌患者,围手术期纳武利尤单抗联合 IRE 可诱导免疫激活相关的病理学缓解并显示抗肿瘤效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Irreversible electroporation (IRE) is a non-thermal ablation technique suited for difficult-to-treat hepatocellular carcinoma (HCC) with 1-year local recurrence (LR) rates above 50%. We hypothesized that peri-procedural immunotherapy could synergize with IRE to decrease local recurrence. APPROACH AND RESULTS: NIVOLEP is a multicenter phase 2 trial evaluating nivolumab combined with IRE in patients with BCLC A HCC. Patients received 2 neoadjuvant nivolumab infusions, IRE with curative intent, and 12 monthly adjuvant nivolumab infusions. Tumor biopsies were performed at baseline and during IRE. The primary endpoint was 1-year local recurrence-free survival (LRFS). In all, 62 HCC nodules (mean size: 30.0 mm) from 43 patients (mean age: 71 y, 88% male, 81% cirrhosis) were considered. All patients received neoadjuvant nivolumab; 35 underwent curative IRE (8 others: 4 IRE failures, 3 HCC progressions, 1 death). After neoadjuvant nivolumab, radiological or pathological response was observed in 24.2% and 26.3% nodules, respectively. One-year LRFS was 70.6% (95% CI: 55.3-85.9), and 2-year overall survival was 74.2% in the intention-to-treat analysis. Grade 3 or 4 adverse events related to nivolumab occurred in 2 patients; 1 patient died due to nivolumab. RNA-sequencing analysis of the tumor after neoadjuvant nivolumab showed an enrichment of pathways associated with leukocyte migration, T cell activation, and CD8+ T and B-cell infiltration associated with pathological response. Circulating protein variations were associated with pathological or radiological responses and local recurrence. CONCLUSIONS: Neoadjuvant and adjuvant nivolumab in BCLC A HCC patients eligible for IRE lead to pathological response related to immune activation and show anti-tumoral effect.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Nahon P, Ziol M, Pan L, et al. Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with early hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial). Hepatology. 2026. PMID: 41950497. doi:10.1097/HEP.0000000000001764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。